Corvus Pharmaceuticals, Inc. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
Corvus Pharmaceuticals, Inc. (CRVS) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $64.34 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-06
- Corvus Pharmaceuticals, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $47.36M, a 145.54% increase year-over-year.
- Corvus Pharmaceuticals, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $16.98M, a 41.67% increase year-over-year.
- Corvus Pharmaceuticals, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $24.32M, a 70.41% increase year-over-year.
- Corvus Pharmaceuticals, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $28.53M, a 90.89% increase year-over-year.
- Corvus Pharmaceuticals, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $84.13M, a 97.34% increase from fiscal 2024.
- Corvus Pharmaceuticals, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $42.63M, a 31.93% decline from fiscal 2023.
- Corvus Pharmaceuticals, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2023 was $62.62M, a 45.09% increase from fiscal 2022.
- Corvus Pharmaceuticals, Inc. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2022 was $43.16M, a 39.58% increase from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $47.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $64.34M 10-Q · filed 2026-08-06 | $88.66M derived: sum of 3 quarters · filed 2026-08-06 | $117.19M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $16.98M 10-Q · filed 2026-05-07 | $41.30M derived: sum of 2 quarters · filed 2026-05-07 | $69.84M derived: sum of 3 quarters · filed 2026-05-07 | $89.12M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $24.32M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $52.85M derived: sum of 2 quarters · filed 2026-03-12 | $72.14M derived: sum of 3 quarters · filed 2026-08-06 | $84.13M 10-K · filed 2026-03-12 |
| 2025-09-30 | $28.53M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $47.82M derived: sum of 2 quarters · filed 2026-08-06 | $59.80M 10-Q · filed 2025-11-04 | $74.08M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $19.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $31.27M 10-Q · filed 2026-08-06 | $45.55M derived: sum of 3 quarters · filed 2026-08-06 | $60.49M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $11.99M 10-Q · filed 2026-05-07 | $26.26M derived: sum of 2 quarters · filed 2026-05-07 | $41.21M derived: sum of 3 quarters · filed 2026-05-07 | $50.00M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $14.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $29.22M derived: sum of 2 quarters · filed 2026-03-12 | $38.01M derived: sum of 3 quarters · filed 2026-03-12 | $42.63M 10-K · filed 2026-03-12 |
| 2024-09-30 | $14.95M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $23.74M derived: sum of 2 quarters · filed 2025-11-04 | $28.36M 10-Q · filed 2025-11-04 | $37.46M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-06-30 | $8.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $13.41M 10-Q · filed 2025-08-07 | $22.52M derived: sum of 3 quarters · filed 2026-03-12 | $41.88M derived: sum of 4 quarters · filed 2026-03-12 |
| 2024-03-31 | $4.62M 10-Q · filed 2025-05-08 | $13.73M derived: sum of 2 quarters · filed 2026-03-12 | $33.09M derived: sum of 3 quarters · filed 2026-03-12 | $49.52M derived: sum of 4 quarters · filed 2026-03-12 |
| 2023-12-31 | $9.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $28.47M derived: sum of 2 quarters · filed 2026-03-12 | $44.90M derived: sum of 3 quarters · filed 2026-03-12 | $62.62M 10-K · filed 2026-03-12 |
| 2023-09-30 | $19.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $35.79M derived: sum of 2 quarters · filed 2024-11-12 | $53.52M 10-Q · filed 2024-11-12 | $68.91M derived: sum of 4 quarters · filed 2025-03-25 |
| 2023-06-30 | $16.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $34.16M 10-Q · filed 2024-08-06 | $49.55M derived: sum of 3 quarters · filed 2025-03-25 | $70.33M derived: sum of 4 quarters · filed 2025-03-25 |
| 2023-03-31 | $17.73M 10-Q · filed 2024-05-07 | $33.12M derived: sum of 2 quarters · filed 2025-03-25 | $53.90M derived: sum of 3 quarters · filed 2025-03-25 | $60.08M derived: sum of 4 quarters · filed 2025-03-25 |
| 2022-12-31 | $15.40M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-25 | $36.17M derived: sum of 2 quarters · filed 2025-03-25 | $42.35M derived: sum of 3 quarters · filed 2025-03-25 | $43.16M 10-K · filed 2025-03-25 |
| 2022-09-30 | $20.77M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $26.95M derived: sum of 2 quarters · filed 2023-11-07 | $27.77M 10-Q · filed 2023-11-07 | $30.27M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-06-30 | $6.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $6.99M 10-Q · filed 2023-08-08 | $9.49M derived: sum of 3 quarters · filed 2024-03-19 | $13.12M derived: sum of 4 quarters · filed 2024-03-19 |
| 2022-03-31 | $810.00K 10-Q · filed 2023-05-08 | $3.31M derived: sum of 2 quarters · filed 2024-03-19 | $6.93M derived: sum of 3 quarters · filed 2024-03-19 | $23.57M derived: sum of 4 quarters · filed 2024-03-19 |
| 2021-12-31 | $2.50M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $6.13M derived: sum of 2 quarters · filed 2024-03-19 | $22.75M derived: sum of 3 quarters · filed 2024-03-19 | $30.92M 10-K · filed 2024-03-19 |
| 2021-09-30 | $3.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $20.25M derived: sum of 2 quarters · filed 2022-11-03 | $28.42M 10-Q · filed 2022-11-03 | $35.96M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-06-30 | $16.63M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $24.80M 10-Q · filed 2022-08-08 | $32.34M derived: sum of 3 quarters · filed 2023-03-28 | $48.08M derived: sum of 4 quarters · filed 2023-03-28 |
| 2021-03-31 | $8.17M 10-Q · filed 2022-05-05 | $15.71M derived: sum of 2 quarters · filed 2023-03-28 | $31.45M derived: sum of 3 quarters · filed 2023-03-28 | $56.44M derived: sum of 4 quarters · filed 2023-03-28 |
| 2020-12-31 | $7.54M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-28 | $23.28M derived: sum of 2 quarters · filed 2023-03-28 | $48.28M derived: sum of 3 quarters · filed 2023-03-28 | $86.38M 10-K · filed 2023-03-28 |
| 2020-09-30 | $15.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-01 | $40.74M derived: sum of 2 quarters · filed 2021-11-01 | $78.84M 10-Q · filed 2021-11-01 | $107.15M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-06-30 | $24.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | $63.09M 10-Q · filed 2021-08-02 | $91.41M derived: sum of 3 quarters · filed 2022-03-10 | $131.25M derived: sum of 4 quarters · filed 2022-03-10 |
| 2020-03-31 | $38.10M 10-Q · filed 2021-04-29 | $66.41M derived: sum of 2 quarters · filed 2022-03-10 | $106.26M derived: sum of 3 quarters · filed 2022-03-10 | $141.28M derived: sum of 4 quarters · filed 2022-03-10 |
| 2019-12-31 | $28.31M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10 | $68.16M derived: sum of 2 quarters · filed 2022-03-10 | $103.18M derived: sum of 3 quarters · filed 2022-03-10 | $141.87M 10-K · filed 2022-03-10 |
| 2019-09-30 | $39.85M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-10-29 | $74.86M derived: sum of 2 quarters · filed 2020-10-29 | $113.55M 10-Q · filed 2020-10-29 | $152.28M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-06-30 | $35.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30 | $73.70M 10-Q · filed 2020-07-30 | $112.43M derived: sum of 3 quarters · filed 2021-03-25 | $166.25M derived: sum of 4 quarters · filed 2021-03-25 |
| 2019-03-31 | $38.69M 10-Q · filed 2020-04-30 | $77.41M derived: sum of 2 quarters · filed 2021-03-25 | $131.23M derived: sum of 3 quarters · filed 2021-03-25 | $151.29M derived: sum of 4 quarters · filed 2021-03-25 |
| 2018-12-31 | $38.73M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-25 | $92.55M derived: sum of 2 quarters · filed 2021-03-25 | $112.60M derived: sum of 3 quarters · filed 2021-03-25 | $132.02M 10-K · filed 2021-03-25 |
| 2018-09-30 | $53.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-29 | $73.88M derived: sum of 2 quarters · filed 2019-10-29 | $93.30M 10-Q · filed 2019-10-29 | $117.20M derived: sum of 4 quarters · filed 2020-03-09 |
| 2018-06-30 | $20.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01 | $39.48M 10-Q · filed 2019-08-01 | $63.38M derived: sum of 3 quarters · filed 2020-03-09 | $112.08M derived: sum of 4 quarters · filed 2020-03-09 |
| 2018-03-31 | $19.42M 10-Q · filed 2019-05-09 | $43.32M derived: sum of 2 quarters · filed 2020-03-09 | $92.02M derived: sum of 3 quarters · filed 2020-03-09 | $156.52M derived: sum of 4 quarters · filed 2020-03-09 |
| 2017-12-31 | $23.90M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-09 | $72.60M derived: sum of 2 quarters · filed 2020-03-09 | $137.10M derived: sum of 3 quarters · filed 2020-03-09 | $173.40M 10-K · filed 2020-03-09 |
| 2017-09-30 | $48.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01 | $113.20M derived: sum of 2 quarters · filed 2018-11-01 | $149.50M 10-Q · filed 2018-11-01 | $248.30M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-06-30 | $64.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-02 | $100.80M 10-Q · filed 2018-08-02 | $199.60M derived: sum of 3 quarters · filed 2019-03-07 | $219.60M derived: sum of 4 quarters · filed 2019-03-07 |
| 2017-03-31 | $36.30M 10-Q · filed 2018-05-03 | $135.10M derived: sum of 2 quarters · filed 2019-03-07 | $155.10M derived: sum of 3 quarters · filed 2019-03-07 | $217.03M derived: sum of 4 quarters · filed 2019-03-07 |
| 2016-12-31 | $98.80M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-07 | $118.80M derived: sum of 2 quarters · filed 2019-03-07 | $180.72M derived: sum of 3 quarters · filed 2019-03-07 | $213.72M 10-K · filed 2019-03-07 |
| 2016-09-30 | $20.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-02 | $81.92M derived: sum of 2 quarters · filed 2017-11-02 | $114.92M 10-Q · filed 2017-11-02 | $122.72M derived: sum of 4 quarters · filed 2018-03-01 |
| 2016-06-30 | $61.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-03 | $94.92M 10-Q · filed 2017-08-03 | $102.72M derived: sum of 3 quarters · filed 2018-03-01 | |
| 2016-03-31 | $33.00M 10-Q · filed 2017-05-04 | $40.80M derived: sum of 2 quarters · filed 2018-03-01 | ||
| 2015-12-31 | $7.80M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-01 | $14.10M 10-K · filed 2018-03-01 | ||
| 2015-09-30 | $6.30M 10-Q · filed 2016-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Apnimed, Inc. (APMD) | United States | $0.899B |